On Tuesday, Absci Corp (NASDAQ: ABSI) opened lower -3.97% from the last session, before settling in for the closing price of $3.02. Price fluctuations for ABSI have ranged from $2.01 to $6.33 over the past 52 weeks.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -29.30%. Company’s average yearly earnings per share was noted 12.37% at the time writing. With a float of $135.76 million, this company’s outstanding shares have now reached $149.75 million.
Absci Corp (ABSI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Absci Corp is 9.72%, while institutional ownership is 65.06%. The most recent insider transaction that took place on Dec 05 ’25, was worth 148,800. In this transaction Director of this company bought 40,000 shares at a rate of $3.72, taking the stock ownership to the 63,320 shares. Before that another transaction happened on Sep 22 ’25, when Company’s Director bought 95,785 for $2.66, making the entire transaction worth $254,788. This insider now owns 113,960 shares in total.
Absci Corp (ABSI) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.25 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.22) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 12.37% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.94% during the next five years compared to -29.30% drop over the previous five years of trading.
Absci Corp (NASDAQ: ABSI) Trading Performance Indicators
Check out the current performance indicators for Absci Corp (ABSI). In the past quarter, the stock posted a quick ratio of 5.89. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 155.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.90, a number that is poised to hit -0.18 in the next quarter and is forecasted to reach -0.67 in one year’s time.
